1 Cyclo-oxygenase (COX) and lipoxygenase (LO) share a common substrate, arachidonic acid. Aspirin and related drugs inhibit COX activity. In a subset of patients with asthma aspirin induces clinical symptoms associated with increased levels of certain LO products, a phenomenon known as aspirin-sensitive asthma. The pharmacological pathways regulating such responses are not known. 2 Here COX-1 and LO activity were measured respectively by the formation of thromboxane B 2 (TXB 2 ) or leukotrienes (LT) C 4 , D 4 and E 4 in whole blood stimulated with A23187. COX-2 activity was measured by the formation of prostaglandin E 2 (PGE 2 ) in blood stimulated with lipopolysaccharide (LPS) for 18 h. 3 No dierences in the levels of COX-1, COX-2 or LO products or the potency of drugs were found in blood from aspirin sensitive vs aspirin tolerant patients. Aspirin, indomethacin and nimesulide inhibited COX-1 activity, without altering LO activity. Indomethacin, nimesulide and the COX-2 selective inhibitor DFP [5,5-dimethyl-3-(2-isopropoxy)-4-(4-methanesulfonylphenyl)-2(5H)-furanone] inhibited COX-2 activity. NO-aspirin, like aspirin inhibited COX-1 activity in blood from both groups. However, NO-aspirin also reduced LO activity in the blood from both patient groups. Sodium salicylate was an ineective inhibitor of COX-1, COX-2 or LO activity in blood from both aspirin-sensitive and tolerant patients. 4 Thus, when COX activity in the blood of aspirin-sensitive asthmatics is blocked there is no associated increase in LO products. Moreover, NO-aspirin, unlike other NSAIDs tested, inhibited LO activity in the blood from both aspirin sensitive and aspirin tolerant individuals. This suggests that NO-aspirin may be better tolerated than aspirin by aspirin-sensitive asthmatics.
Introduction
Cyclo-oxygenase (COX) and lipoxygenase (LO) are two main pathways involved in the metabolism of arachidonic acid (AA). COX catalyses the synthesis of prostaglandins (PG) and thromboxane (Smith et al., 1991) . COX exists in two isoforms, COX-1 is constitutively expressed whilst COX-2 is induced by in¯ammatory stimuli (Mitchell & Warner, 1999) . Non-steroidal anti-in¯ammatory drugs (NSAIDs), which include aspirin are a group of chemically distinct compounds which inhibit both COX-1 and COX-2 activity. COX-2 is the predominate isoform present in a range of human in¯amma-tory diseases and most recently selective inhibitors of COX-2 (e.g. celecoxib and rofecoxib) have been developed and introduced for the treatment of arthritic disease. By contrast, inhibitors of COX-1 (or COX-2) are not recommended for the treatment of in¯ammatory airway diseases such as asthma. This is despite the identi®cation of active enzyme in human airway cells Mitchell et al., 1994) . In fact NSAIDs are counter-indicated for asthmatics and in a sub-population induces symptoms such as rhinorrhea, nasal congestion and severe nasal polyps. Asthmatic patients who are sensitive to aspirin, and possibly other NSAIDs, are commonly referred to as aspirin-sensitive asthmatics.
evidence that leukotrienes (LT) C 4 , D 4 and E 4 derived from the 5-lipoxygenase (5-LO) pathway are involved. These LTs are pro-in¯ammatory in nature, causing bronchoconstriction and migration of in¯ammatory cells into the airway. The levels of LTC 4 , D 4 and E 4 are increased after ingestion of drugs such as aspirin in sensitive patients and symptoms are relieved by 5-LO inhibitors as well as by LT antagonists (Christie et al., 1991; Nasser et al., 1994) . Furthermore recent studies suggest that asthma could be associated with expression of 5-LO in blood leukocytes (Koshino et al., 1998) and/or mutations in the gene promoter for the 5-LO activating protein (Koshino et al., 1999) . There are three ways in which inhibition of COX activity are thought to regulate 5-LO products. Firstly, inhibition of COX may increase the level of free arachidonic acid available in cells after stimulation. Secondly, the blockade of PG (e.g. PGE 2 ) formed by COX is thought to remove an endogenous`brake' on the formation of LTs, which has been demonstrated in human eosinophils and neutrophils (Docherty & Wilson, 1987; Tenor et al., 1996) . Finally, where COX-2 predominates, aspirin may induce the production of 5-LO products via the modi®cation of metabolites formed . Thus, aspirin blocks the enzymatic activities of COX-1 irreversibly. By contrast aspirin merely diverts the metabolite formed by COX-2 away from PGH 2 and towards 15-hydroxyeicosatetreanoic acid (15-HETE) (Holtzman et al., 1992) . This 15-HETE can then be further metabolized by 5-LO to the novel 15-epilipoxins (Claria & Serhan, 1995) .
However, none of the above hypotheses generated to explain aspirin-sensitive asthma have been fully tested and thereby proven or disproved. Here we have used a modi®ed whole blood assay to compare the relative sensitivity of COX-1 vs COX-2 in tissue from aspirin-sensitive and aspirin tolerant individuals. In parallel we have studied how inhibiting either COX-1 or COX-2 in¯uences the production of 5-LO products in blood from aspirin sensitive patients and in blood from healthy control donors. Some of these results have been presented in abstract form (Gray et al., 2000) .
Methods

Characterization of aspirin sensitive group
All subjects in the`aspirin sensitive asthma' group had a history of aspirin-induced reaction. They developed a respiratory type reaction (asthma+rhinoconjunctivitis) following aspirin or NSAID ingestion. These patients had their aspirin-sensitivity con®rmed by an intranasal challenge with lysine-aspirin. These were carried out in controlled circumstances, with full resuscitative facilities. Brie¯y, each patient was challenged with placebo, followed by two incremental doses of lysine-aspirin (4 and 8 mg), in a single-blind fashion. Parameters measured before and after the challenge included nasal symptom score, nasal inspiratory peak¯ow, peak expiratory¯ow rate, and acoustic rhinometry (measuring change in nasal minimum cross-sectional area, and volume). A change of 25% (reduction) in nasal cross-sectional area, and volume (between 0 ± 7 cm) was taken as con®rmation of a positive challenge. All patients were o their intranasal steroids for 1 week prior to the challenge. All patients had characteristic nasal polyps.
Characterization of control group
Blood donors from the control (aspirin tolerant and nonasthmatic) group had no history of aspirin sensitivity and con®rmed that they took aspirin and related drugs routinely.
COX-1 and COX-2 activity in human blood ) and drugs were added (18 h incubation time) as in the COX-1 protocol. Plates were then spun and plasma removed and frozen. Using radioimmunoassay, concentrations of TXB 2 (as a measure of TXA 2 formation and COX-1 activity) or PGE 2 (as a measure of COX-2 activity) were determined in plasma samples from COX-1 or COX-2 assays, respectively .
5-LO activity in whole blood
Levels of total LTC 4 , D 4 , and E 4 were measured by a common enzyme immunoassay, according to the manufacturer's instructions, as an indicator of 5-LO products. The formation of LTs by cells requires both the release of substrate arachidonic acid and activation of 5-LO activating protein (FLAP). Stimulation of whole blood with A23187 provides both of these necessary events. Thus, as expected, samples obtained under identical conditions as for the COX-1 contained clear and consistent elevations in the level of LTs. However, samples taken under conditions identical to those for the COX-2 assay, where A23187 is not added, LTs levels were undetectable. Thus, all drug incubation studies were performed on blood treated under identical conditions to those described for the COX-1 assay.
Materials
Aspirin, sodium salicylate, indomethacin, nimesulide, DMSO and Ca ionophore A23187 were obtained from Sigma Chemical Co (Poole, Dorset, U.K.). NicOx (Sophia Antipolis, France) supplied NO-aspirin (NCX 4016). DFP was a gift from Merck-Frosst Labs (Pointe Claire, PQ, Canada). Heparin was provided by National Veterinary supplies (Stoke on Trent, U.K. 
Statistical analysis
All values in the text, ®gures and table are expressed as the mean+s.e.mean of n observations. Concentration response curves were ®tted using a sigmoidal regression with variable slope and statistical analysis was performed (raw values expressed as a percentage of control) using a two-way analysis of variance (ANOVA) and a Bonferroni post test. Students t-test was used to analyse the IC 50 s for the concentration curves. A P value of 50.05 was considered statistically signi®cant.
Results
Effects of NSAIDs on COX-1 activity
Unstimulated blood from aspirin-sensitive or healthy donors contained low levels of TXB 2 (4+2 vs 3+1 ng ml 71 respectively). However, when stimulated with Ca ionophore A23187, large amounts of TXB 2 (control: 56+10 vs aspirinsensitive: 75+8 ng ml Table 1 ) as an inhibitor of COX-1 activity in blood from control donors vs aspirin sensitive individuals. Neither DFP nor sodium salicylate had any eect on COX-1 activity in blood from either aspirin-sensitive or control donors ( Figure  2 ).
Effects of NSAIDs on COX-2 activity
In unstimulated blood incubated under sterile conditions for 18 h PGE 2 levels were undetectable (detection limit: 0.7 ng ml 71 ). When challenged with LPS for 18 h, blood from control as well as aspirin-sensitive patients released large amounts of PGE 2 (control: 68+26 vs aspirin sensitive donors: 29+8 ng ml
71
). The levels of PGE 2 (index of COX-2 activity) were lower in LPS stimulated blood from aspirinsensitive than tolerant donors, however this did not reach statistical signi®cance (P40.05; unpaired Student t-test). Indomethacin, nimesulide or DFP caused concentrationdependent inhibitions of COX-2 activity in blood from both groups ( Figure 3) . As was seen for its activity on COX-1, nimesulide was a more potent inhibitor of COX-2 activity in blood from control compared to aspirin-sensitive donors (P50.05 for IC 50 values tested by Students unpaired twotailed t-test; P50.05 for whole curve analysis using two-way ANOVA; Table 1, Figure 3) . NO-aspirin, aspirin or sodium salicylate induced only weak inhibitions of COX-2 activity in whole blood and no dierences were apparent in the inhibition of COX-2 activity in blood from control vs aspirin-sensitive patients (Figure 4) .
LO activity
Basal release of total 5-LO products (LTC, D and E 4 ) in blood from control or aspirin-sensitive donors was undetectable. However, when stimulated with A23187, large amounts of LTs were released by blood from both patient groups (control: 39+3 vs aspirin sensitive asthmatics: 44+4 ng ml
71
). In each case, no eect on LT production was seen in paired samples of blood where COX-1 activity had been inhibited by indomethacin, nimesulide or aspirin (n=4; data not shown). The lack of eect of COX inhibition on corresponding LO activity was apparent at all concentrations of the NSAIDs used. By contrast, albeit at high concentrations, when blood was treated with NO-aspirin, 5-LO activity was inhibited. The inhibitory eect of NO-aspirin on LT production was signi®cant (P50.05 for eect of concentration on whole curve) and of a similar magnitude in blood from both patient groups ( Figure 5) .
When blood was stimulated with LPS to induce COX-2, LT levels did not increase and remained undetectable (n=3; data not shown).
Discussion
Aspirin-sensitive asthma is a signi®cant clinical problem aecting between 5 and 20% of the asthmatic population (Babu & Salvi, 2000) . The common consensus of opinion suggests that aspirin-sensitive asthma has a biochemical origin and is mediated by blocking the COX pathway. However, there are still a number of important questions about this condition that remain unanswered or controversial. Thus, the relative relationship between COX-1, COX-2, 5-LO and LTC 4 synthase activity in aspirin sensitive asthma is unclear. In the current study we have used the whole blood assay for COx-1 and COX-2 and demonstrated no dierence in potency of standard NSAIDs (except for nimesulide) or the COX-2 selective inhibitor DFP of activity in blood from aspirin sensitive asthmatics compared to tolerant control subjects. Furthermore, we have shown that when COX activity is blocked with NSAIDs, including aspirin, 5-LO products are not released in excess. Finally, we found that NO-aspirin, unlike authentic aspirin, reduced LT production in blood from aspirin-sensitive and aspirin tolerant individuals.
Aspirin-sensitivity is a complex clinical cohort. The organ systems in¯uenced by aspirin ingestion inclue the lungs, skin, eyes and gastro-intestinal tract. Furthermore, it is not fully established that all forms of aspirin-sensitivity are a true NSAID-class eect or if, in some cases, the response is due to allergy based mechanisms to the drug itself and independent of eects on PG formation. Indeed, the vast majority of studies investigating the mechanisms of aspirin-sensitive asthma use a single NSAID, namely aspirin as the chosen COX inhibitor. Nevertheless, numerous studies have established that, in sensitive individuals, increased levels of the 5-LO product, LTC 4 and its derivatives are present in the urine and correlate to the severity of symptoms (Knapp et al., 1992) . This observation together with others showing that (i) aspirin-sensitivity is associated with the increased expression Figure 1 The inhibitory eect of (a) NO-aspirin, (b) aspirin, (c) indomethacin and (d) nimesulide on COX-1 activity in blood from healthy donors and aspirin-sensitive asthmatics (ASA). Data represent enzyme activity calculated as percentage of control response from each group (n=5 ± 6). The IC 50 of each drug was calculated using PRISM (GraphPad) and analysed with student's t-test (n=5 ± 6). *P50.05. Figure 2 The inhibitory eect of (a) DFP and (b) sodium salicylate on COX-1 activity in blood from healthy donors and aspirinsensitive asthmatics (ASA). Data represent enzyme activity calculated as percentage of control response from each group (n=5 ± 6).
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We found that LTC 4 , D 4 and E 4 were released in similar levels by A23187-stimulated blood from the two patient groups. Thus we did not observe a predicted elevation in Figure 3 The inhibitory eect of (a) indomethacin, (b) nimesulide and (c) DFP on COX-2 activity in blood from healthy donors and aspirin-sensitive asthmatics (ASA). Data represent enzyme activity calculated as percentage of control response from each group (n=5 ± 6). Figure 4 The inhibitory eect of (a) NO-aspirin, (b) aspirin and (c) salicylate on COX-2 activity in blood from healthy donors and aspirin-sensitive asthmatics (ASA). Data represent enzyme activity calculated as percentage response from each group (n=5 ± 6). LTC 4 synthase products in blood from aspirin-sensitive patients. Similarly no dierences in the levels of either TxB 2 (for the COX-1 assay) or PGE 2 (for the COX-2 assay) were seen in stimulated blood from the two patient groups. Furthermore, we found that when COX-1 activity in whole blood stimulated with A23187 was blocked with aspirin, indomethacin or nimesulide there was no associated increase in LTC 4 or its derivative in samples from either aspirintolerant control donors or from aspirin-sensitive asthmatic patients. Others have shown using leukocytes isolated from aspirin-sensitive patients that aspirin alone, or in combination with N-formyl-methionyl-leucyl-phenylalanine, does not increase LT release (Pierzchalska et al., 2000) . By contrast, May et al. (1999) , describing results for a cellular antigen stimulation test, found that aspirin in combination with C5a in vitro caused leukocytes from aspirin intolerant patients to release higher levels of LTs than control subjects. Interestingly, May and co-workers showed that indomethacin but not diclofenac or ibuprofen displayed cross-reactivity with aspirin in their model. Thus, the data from our current study and others (Pierzchalska et al., 2000) suggest that, in peripheral cells at least, aspirin-sensitivity is not associated with a biochemical disruption in the balance between COX and LO products. Whether or not the same is true for cells of the airway remains the subject of investigation.
As mentioned above, the potency of aspirin or indomethacin as inhibitors of COX-1 activity in whole blood was the same in samples from aspirin-sensitive and aspirin tolerant patients. In addition, when COX-2 was induced in blood from aspirin-sensitive asthmatics, the potency of the COX-2 selective inhibitor, DFP was equivalent to that seen in blood from tolerant donors. This observation suggests that there is no anomaly in the biochemical properties of the COX-1 or COX-2 in aspirin-sensitive asthma. By contrast to aspirin, indomethacin or DFP, we found that the potency of nimesulide was slightly, but signi®cantly, reduced in both the COX-1 and COX-2 assays using blood from aspirinsensitive donors. The reason why the potency of nimesulide, but not other NSAIDs, may be altered in aspirin-sensitive asthma is not clear. Moreover, the relevance of such small dierences may not be manifest in an in vivo setting. Nevertheless, the reasons why this observation has been made should be discussed. Nimesulide is not a pro-drug and as such does not require metabolism for activity. However, it may be that nimesulide itself is metabolized or bound in some way that renders it less active in aspirin-sensitive asthma. Interestingly, in a limited number of studies, nimesulide has been given to aspirin-sensitive asthmatics without inducing symptoms. Nimesulide displays a moderate selectivity as an inhibitor of COX-2 over COX-1 . Recently another COX-2 selective NSAID, rofecoxib, has been given to aspirin-sensitive asthmatics without inducing symptoms (Szczeklik et al., 2001) . The tolerability of COX-2 selective (or COX-1 sparing; Vane & Warner, 2000) drugs has led to the suggestion that there is a speci®c involvement of COX-1 in aspirin-sensitivity (Szczeklik et al., 2001) . This concept may appear, at ®rst, counterintuitive since asthma is a chronic in¯ammatory disease with the certain presence of COX-2 at the site of in¯ammation (Sousa et al., 1997) . However, we have recently shown that, despite the presence of active COX-2 in cytokine-stimulated human airway smooth muscle, the ability of NSAIDs to stimulate the release of granulocyte-macrophage colony stimulating factor (the presence of which is associated with allergic airway disease) correlated with their selectivity as inhibitors of COX-1 (Lazzeri et al., 2001) .
In our assay, aspirin appears to produce only a weak inhibition of COX-2; this is because the incubation time required to observe COX-2 activity allows for almost total breakdown of the drug to salicylate (Higgs et al., 1987) . Salicylate itself is very easily displaced by endogenous or exogenous substrate . Thus, under these conditions, aspirin (i.e. in salicylate form) as well as authentic salicylate are weak inhibitors of COX-2 activity in the blood of either patient group.
NO-aspirin is a relatively novel pharmaceutical preparation that has been shown to have fewer gastrointestinal side eects in the rat than authentic aspirin (Takeuchi et al., 1998) . We found that, like aspirin, NO-aspirin inhibited COX-1 activity in the blood of aspirin-sensitive asthmatics and of aspirin tolerant controls. However, we also found that, unlike any of the other NSAIDs tested, NO-aspirin inhibited the release of LTs by blood from both patient groups. Our understanding of the pharmacology of NO-aspirin is incomplete. However, it has been suggested that the release of NO or a related NOmoiety, is responsible for the gastroprotective eects of this compound. Speci®cally, NO-NSAIDs are examples of bifunctional donors, where the pharmacological actions of a drug class like NSAIDs are retained and conjugated to a NOmoiety, which conceivably releases NO. There are two classes of NO-NSAIDs depending on whether they contain the nitrate ester functional group, as is the case for NO-aspirin or a S-nitrosothiol. It is thought that cleavage at the ester bond, by esterases releases a NO species. The structure of NOaspirin consists of several ester groups, acetate, benzoate and nitrate esters. One study has investigated the metabolism of NO-aspirin in vitro, by incubating it with sub-cellular fractions of rat liver (Carini et al., 2001) . Salicylate and benzenemethanol-3-hydroxy-a-nitrate (HBN) are the main metabolites. The latter is then rapidly metabolized to an unknown compound and the remainder converted to benzenemethanol-3-hydroxy (HBA). Carini et al. (2001) postulate that NO-aspirin undergoes ®rst pass metabolism in the liver and the biotransformation of HBN, which may lead to the production of excretory nitrates or the conversion of bioactivate NO. This research group has also provided evidence using nitrosylhemoglobin complex (marker of NO Figure 5 The eect of NO-aspirin on LT production by Ca ionophore A23187 stimulated blood from healthy donors and aspirin-sensitive asthmatics (ASA). Data represent enzyme activity calculated as percentage response from each group (n=4).
formation) that NO-aspirin slowly releases NO, which is detectable in the blood of a rat given orally.
Thus, it is possible that NO-aspirin inhibits LT release by stimulated whole blood via an NO-like pathway. This notion is supported by some reports in the literature. For example, endogenously released NO inhibits the production of 5-LO metabolites in macrophages (Brunn et al., 1997) , an eect that may occur at the level of 5-LO activating protein (Coey et al., 2000) . NO has also been shown to interfere with the iron binding site of 5-LO (Kanner et al., 1992) . However, the precise mechanisms of action of NO-aspirin on LTs synthesis remains the subject of investigation.
In conclusion, we found no dierences in the pharmacology of standard and novel NSAIDs on COX-1 or COX-2 activity in blood from aspirin-tolerant vs aspirin-sensitive individuals. Furthermore, when COX activity was blocked we did not see an associated increase in the level of LTs released. Finally, unlike authentic aspirin, NO-aspirin inhibited the release of LTs by stimulated blood from either patient group. These observations suggest that, in blood borne cells there is (i) no defect in the biochemical function of COX-1 or COX-2, that (ii) 5-LO and/or LTC 4 synthase is not rate limiting and that (iii), there is no COX-dependent brake on LT production. NO-aspirin reduced the production of LT in vitro suggesting that this form of aspirin may have a therapeutic relevance for the treatment of in¯ammatory conditions where LTs are elevated, e.g. asthma. However, this hypothesis would require further and more direct experimentation before ®rm conclusions could be drawn.
